(Total Views: 629)
Posted On: 11/09/2021 7:03:33 PM
Post# of 154001
What's happening here!
Another fine post to share:
RANTES
Very damaging change to the Amerex case. NSF Executive in charge of Amerex emailed CYTODYN with undisputable agreement that CYTODYN owns the data. He was puzzled by why Kazem Kazempour, Amarex’s CEO won't release the data. This is going to get very interesting.
Amended Complaint for Declaratory and Injunctive Relief
INTRODUCTION 1.
CytoDyn brings this Complaint to protect 67 patients with treatment-resistant HIV and 25 patients with non-alcoholic steatohepatitis (a kind of liver disease) that are currently receiving CytoDyn’s drug in clinical trials. The safety of these patients is being threatened by Amarex, the clinical research organization managing the trials under contracts with CytoDyn. Amarex is threatening to end these trials and cease all safety monitoring for them, while simultaneously cutting off CytoDyn from accessing the clinical trial databases necessary for it to take over management of the trials. It is undisputed that CytoDyn owns the data, as acknowledged by the NSF executive in charge of Amarex, Martin Lush. Mr. Lush wrote in a June 9, 2021 email to CytoDyn that “[y]ou own every piece of data generated by the CRO. . . . I’m just trying to better understand why KK [Kazem Kazempour, Amarex’s CEO] is refusing to release non executable data files since this is usually a contractual requirement.” CytoDyn is bringing this action to compel Amarex to provide full access to the data—which CytoDyn owns—to protect the integrity of these critical studies and to protect the patients receiving CytoDyn’s drug"
Another fine post to share:
RANTES
Very damaging change to the Amerex case. NSF Executive in charge of Amerex emailed CYTODYN with undisputable agreement that CYTODYN owns the data. He was puzzled by why Kazem Kazempour, Amarex’s CEO won't release the data. This is going to get very interesting.
Amended Complaint for Declaratory and Injunctive Relief
INTRODUCTION 1.
CytoDyn brings this Complaint to protect 67 patients with treatment-resistant HIV and 25 patients with non-alcoholic steatohepatitis (a kind of liver disease) that are currently receiving CytoDyn’s drug in clinical trials. The safety of these patients is being threatened by Amarex, the clinical research organization managing the trials under contracts with CytoDyn. Amarex is threatening to end these trials and cease all safety monitoring for them, while simultaneously cutting off CytoDyn from accessing the clinical trial databases necessary for it to take over management of the trials. It is undisputed that CytoDyn owns the data, as acknowledged by the NSF executive in charge of Amarex, Martin Lush. Mr. Lush wrote in a June 9, 2021 email to CytoDyn that “[y]ou own every piece of data generated by the CRO. . . . I’m just trying to better understand why KK [Kazem Kazempour, Amarex’s CEO] is refusing to release non executable data files since this is usually a contractual requirement.” CytoDyn is bringing this action to compel Amarex to provide full access to the data—which CytoDyn owns—to protect the integrity of these critical studies and to protect the patients receiving CytoDyn’s drug"
(14)
(0)
